The present invention provides a highly safe non-lamellar liquid crystal-forming composition. The present invention relates to a non-lamellar liquid crystal-forming composition comprising a phospholipid and an amphipathic compound represented by the following general formula (I), wherein X and Y each denotes a hydrogen atom or together denote an oxygen atom, n denotes the integer 1 or 2, m denotes the integer 1 or 2, and R denotes a hydrophilic group having one or more hydroxyl groups, and wherein the composition has an increased biocompatibility by the phospholipid.

##STR00001##

The present invention provides a composition for improving vascular endothelial function, comprising: an ingredient selected from a monounsaturated fatty acid having 20 carbon atoms or more, a salt thereof, and an ester thereof as an active ingredient, in which the ratio of the monounsaturated fatty acid having 20 carbon atoms or more to the total fatty acids in the composition is 10 wt % or greater. The present invention also provides a composition for improving sleep, comprising an ingredient selected from a monounsaturated fatty acid having 20 carbon atoms or more, a salt thereof, and an ester thereof as an active ingredient.

The present invention provides a composition for improving vascular endothelial function, comprising: an ingredient selected from a monounsaturated fatty acid having 20 carbon atoms or more, a salt thereof, and an ester thereof as an active ingredient, in which the ratio of the monounsaturated fatty acid having 20 carbon atoms or more to the total fatty acids in the composition is 10 wt % or greater. The present invention also provides a composition for improving sleep, comprising an ingredient selected from a monounsaturated fatty acid having 20 carbon atoms or more, a salt thereof, and an ester thereof as an active ingredient.

The present invention provides a composition for improving vascular endothelial function, comprising: an ingredient selected from a monounsaturated fatty acid having 20 carbon atoms or more, a salt thereof, and an ester thereof as an active ingredient, in which the ratio of the monounsaturated fatty acid having 20 carbon atoms or more to the total fatty acids in the composition is 10 wt % or greater. The present invention also provides a composition for improving sleep, comprising an ingredient selected from a monounsaturated fatty acid having 20 carbon atoms or more, a salt thereof, and an ester thereof as an active ingredient.

The present disclosure provides lipid emulsions comprising at least 20 percent (w/v) lipid with an average particle size of about 200 to about 300 nm, and use thereof to treat subjects in need of lipid emulsion therapy.

The present disclosure provides lipid emulsions comprising at least 20 percent (w/v) lipid with an average particle size of about 200 to about 300 nm, and use thereof to treat subjects in need of lipid emulsion therapy.

Some aspects of the invention provide for a method of treating Alzheimer's Disease, Mild Cognitive Impairment, Frontotemperal Dementia, Amyotrophic Lateral Sclerosis and/or Multiple Sclerosis using polyunsaturated fatty acids which are modified in certain positions to attenuate oxidative damage by Reactive Oxygen Species (ROS) and/or suppress the rate of formation of reactive products and toxic compounds.

Some aspects of the invention provide for a method of treating Alzheimer's Disease, Mild Cognitive Impairment, Frontotemperal Dementia, Amyotrophic Lateral Sclerosis and/or Multiple Sclerosis using polyunsaturated fatty acids which are modified in certain positions to attenuate oxidative damage by Reactive Oxygen Species (ROS) and/or suppress the rate of formation of reactive products and toxic compounds.

The present invention relates to a new triglyceride, of the formula 2R-TG (C18:2, 9z, 12z; C16:0; C18:1, 9z), extracted from an extract of the Macrocybe titans fungus. Likewise, its use as a medicine and its different clinical applications in the treatment of diseases regulated by the actin cytoskeleton are contemplated. Its use as an antitumoral agent in cancer diseases is mainly contemplated. Finally, the invention relates to the process for obtaining the Macrocybe titans extract that comprises the triglyceride of the invention.

The present invention relates to a new triglyceride, of the formula 2R-TG (C18:2, 9z, 12z; C16:0; C18:1, 9z), extracted from an extract of the Macrocybe titans fungus. Likewise, its use as a medicine and its different clinical applications in the treatment of diseases regulated by the actin cytoskeleton are contemplated. Its use as an antitumoral agent in cancer diseases is mainly contemplated. Finally, the invention relates to the process for obtaining the Macrocybe titans extract that comprises the triglyceride of the invention.